OptiBiotix Health PLC

OptiBiotix’s SlimBiome gathers steam as subsidiary eyes potential IPO

Life sciences firm OptiBiotix Health plc (LON:OPTI) has clinched a number of deals for its SlimBiome weight loss product as the company eyes up a potential initial public offering (IPO). Founder and CEO Stephen O'Hara tells Proactive London how OptiBiotix is changing from an R&D company to a business with greater commercial focus with a number of new deals in 2019 and our prodcuts migrating into other territories.
The group has just inked an agreement with Indian firm Zeon Lifesciences Ltd, granting it an exclusive licence to manufacture and supply SlimBiome in the return in return for a 50% share of the profits.

Quick facts: OptiBiotix Health PLC

Price: £0.48

Market: AIM
Market Cap: £41.01 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...



Full interview: European healthcare broker sets 97p price target for...

OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara speaks to Proactive London following a research note whcih has been published on the company by Goetz partners - which has set OPTI a price target of 97p. O'Hara says Goetz partners are a leading European Investment Bank and broking firm and...

1 week, 4 days ago

2 min read